CollPlant Biotechnologies (CLGN) Net Income towards Common Stockholders (2017 - 2026)

CollPlant Biotechnologies (CLGN) has 10 years of Net Income towards Common Stockholders data on file, last reported at -$3.1 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 89.02% year-over-year to -$3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$38.6 million (down 255.54% YoY) and the FY2025 annual result came in at -$39.9 million, down 1.67% from the prior year.
• Net Income towards Common Stockholders climbed to -$3.1 million in Q1 2026, from -$32.0 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $0.51 in Q2 2023 to a low of -$32.0 million in Q4 2025.
• A 5-year average of -$3.5 million and a median of $0.28 in 2025 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders jumped 237.93% — and 2023, when it sank 1287948817.95%.
• Tracing CLGN's Net Income towards Common Stockholders over 5 years: stood at $0.39 in 2022, then tumbled by 1287948817.95% to -$5.0 million in 2023, then grew by 6.15% to -$4.7 million in 2024, then slumped by 578.47% to -$32.0 million in 2025, then surged by 90.26% to -$3.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$3.1 million (Q1 2026), -$32.0 million (Q4 2025), and -$3.5 million (Q3 2025), per Business Quant data.